Skip to main content

MS treatment in Poland started sooner, reached more people

By MS Buddy ·

Summarized from Neurologia i neurochirurgia polska, Nov 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Observational study · 23,871 people with MS treated through Poland's national drug program

Research by Katarzyna Kapica-Topczewska, Bartosz Karaszewski and 10 colleagues at the Medical University of Bialystok, the Medical University of Warsaw and 6 other institutions in Poland.

How did access to MS treatment and drug choices change in Poland?

Key Takeaway

In Poland, more people with MS received treatment, started it sooner, and received stronger drugs more often.

Muted blue paths widen and join across soft gray layers on an off-white background.
Credibility
Interest
Share:1 min read

What They Found

The number of people receiving MS treatment in Poland rose from 1,569 in 2013 to 23,871 in 2024. For people with MS that has flare-ups, the time from diagnosis to starting treatment fell. Among those starting a first treatment, the typical wait fell from about eight months to about two months. Stronger drugs accounted for about 48% of treatments by the end of 2024. Access to treatment still differed across regions.

Who Should Care and Why

The study examined people with MS treated through Poland's national drug program. Most had MS with flare-ups. The program also treated people with progressive MS, which worsens over time. The findings describe how treatment access and drug use changed across Poland. They do not show whether similar changes happened in other countries.

Important Considerations

You should know this was an observational study of national treatment records, not a test of which drugs work best. The records counted 23,871 people receiving treatment in 2024, but the abstract does not give a total for the whole study. You cannot tell from these records whether starting treatment sooner improved people's health.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Neurologia i neurochirurgia polska by et al.. Reproduced from the PubMed record.

In recent years, the therapeutic landscape of multiple sclerosis (MS) has evolved substantially, with the increasing availability of disease-modifying therapies (DMTs) and a shift toward early use of high-efficacy therapies (HET). This study aimed to evaluate nationwide trends in MS treatment in Poland. This observational, multicenter study was based on real-world data extracted from the Therapeutic Program Monitoring System (SMPT), covering patients treated within the Polish National Health Fund drug program between 2013 and 2024. The analysis included trends in patient numbers, disease phenotypes, and use of specific DMT classes. Data were analyzed descriptively at the national and regional levels. The number of treated patients increased more than 15-fold, from 1,569 in 2013 to 23,871 in 2024. The median time from diagnosis to treatment initiation decreased substantially over the study period. Among first-line patients with relapsing-remitting MS (RRMS), it decreased from approximately 8 months in 2013-2015 to 2-2.5 months in 2020-2024. Among second-line patients with RRMS, including those with treatment failure or highly active disease, it decreased from 5-6 years in 2013-2015 to 9 months in 2023-2024. RRMS remained the most common phenotype (90.3% in 2024); however, the proportion of progressive MS (secondary progressive MS and primary progressive MS: 4.5% and 4.6% in 2024, respectively) increased following the inclusion of dedicated therapies into the program. A marked shift in treatment patterns was observed, from platform therapies to HET, with HET accounting for approximately 48% of all treatments at the end of 2024. Anti-CD20 monoclonal antibodies became the dominant therapeutic class (34.3%) by 2024. Despite overall expansion, regional disparities in treatment access persisted. MS treatment in Poland underwent a significant transformation, characterized by expanded and faster access to therapy and a shift toward high-efficacy treatments. These changes reflect the modernization of the national treatment landscape and extensive educational efforts resulting in closer alignment with contemporary therapeutic strategies.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Rounded stem cells with visible nuclei float against a muted blue-gray background.
MS stem cell transplants mostly done without admission

11/19/2026

A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be

Read More
Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Paper nerve branches sit within a curved protective layer, with most small paper shapes outside and a few nearby.
Stem cell transplants curb disease activity in active MS

11/19/2026

A review finds lasting control of disease activity after stem cell transplants in selected people wi

Read More
Two curving ribbons, one with fewer loose knots; the knots on both ribbons are the same size and length.
MS drugs cut relapses but did not change relapse recovery

11/19/2026

Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan

Read More
Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More
Two paper paths meet at an open junction, surrounded by layered shapes in muted colors.
When older adults with MS should stop drugs remains unclear

11/15/2026

A survey of 24 Israeli MS specialists found agreement on weighing more than age when treating older

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.